by Raynovich Rod | Dec 16, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update after close 12/16…IBB up 2.25%, XBI up 4.45% Rayno Life Science Big Movers Rayno Biopharma ABBV up 2.2%,ALKS up 8.12%, BIIB up 3.52%, ARRY up 20.63 %, CRIS up 6.27%, FCSC up 5%, GERN up 4.42%,RXDX up 2.92% and SGEN up 4.93%. Rayno Dx and Tools ABAX up...
by Raynovich Rod | Dec 10, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Tradeable Intermediate Bottom Today 12:36P… 12/15 GILD 102.8,IBB 331 Update at Close Update…Sunday 12/13/15…Grim Outlook…Risk Off The market sunk further Friday afternoon after 3p for a NASDAQ close at 4933 off 2.33% (up 4.17% YTD) for the...
by Raynovich Rod | Dec 3, 2015 | Biopharmaceuticals, Macro
Biotech Sell-Off Stops Bear Market Rally After a strong November and a rally from October lows biotech stocks broke down today along with the overall market. Keep in mind that it has been a bear market rally with expectations of a seasonal move up. There are plenty of...
by Raynovich Rod | Dec 1, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Look for Growth in Emerging Small Cap Drug Stocks Many stocks were in the red Monday with healthcare a lagging sector down 1%. Many investors await economic data later this week and the mid-December meeting for the FED. Biotech stocks are also weak today with the...
by Raynovich Rod | Nov 25, 2015 | Biopharmaceuticals
Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants...
by Raynovich Rod | Nov 19, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable...
by Raynovich Rod | Nov 13, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB...
by Raynovich Rod | Nov 9, 2015 | Biopharmaceuticals
Small Caps Hot, Large Caps Not Curis (CRIS) and Fibrocell Science (FCSC) Lead the Way Up Biotech stocks could not extend last month’s rally in choppy trading that left major indices up but off mid-week highs. The healthcare sector sold off on continued pricing...
by Raynovich Rod | Oct 30, 2015 | Biopharmaceuticals
Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly...
by Raynovich Rod | Oct 27, 2015 | Biopharmaceuticals
10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD,...
